The initial public offering of Corona Remedies saw strong investor interest, being subscribed more than 137x from 8-10.

The Rs 655.37-crore initial public offering (IPO) of Crorona Remedies mobilised Rs 195 crore from anchor investors.

Ahead of the Dalal Street debut, the grey market premium is indicating a robust listing gain of around 32 per cent, according to the platforms that track unlisted market space.

Corona Remedies launched its IPO today to raise more than Rs 655 crore entirely through an offer for sale (OFS) of shares with no fresh issue component.

As per the latest update, the company’s shares are trading at Rs 1,353 in the unlisted markets. This indicates a premium of nearly 28% over the upper price band. The company has fixed the price band ...

Corona Remedies made a remarkable debut on the stock market, opening with a significant premium. The company's Rs 655-crore IPO was massively oversubscribed, attracting strong interest from ...

Corona Remedies shares opened at ₹1,470 on the NSE, a premium of ₹408 or 38 per cent from the issue price of ₹1,062 ...

Track Corona Remedies share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial reports, annual & quarterly results, and profit & ...

Corona Remedies sold its shares in the price band of Rs 1,008-1,062 apiece, applied for a minimum of 14 shares and its multiples to raise Rs 655.37 crore between December 8-10.